DelSiTech: What are the benefits of silica-based drug delivery?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: DelSiTech: What are the benefits of silica-based drug delivery?
Released on: June 23, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Lasse Leino, CEO of Delsitech discusses the technology behind their biodegradable silica-based small molecule drugs, biopharmaceuticals and viral vectors.
  • Summary
  • Transcript
  • Participants
  • Company
Lasse Leino, CEO of Delsitech discusses the technology behind their biodegradable silica-based small molecule drugs, biopharmaceuticals and viral vectors.
Lasse Leino, CEO of Delsitech discusses the technology behind their biodegradable silica-based small molecule drugs, biopharmaceuticals and viral vectors.
Dr. Leino is the company’s President and Chief Executive Officer and has more than 18 years life science business experience. He is the founder and former President and CEO of BioCis Pharma Ltd as well as the first CEO and COO of Laurantis Pharma Ltd. Previously, Dr. Leino has worked in various R&D management positions in Orion Pharma, BioTie Therapies Ltd, and AstraZeneca in Lund, Sweden. Dr. Leino holds a PhD in biochemistry and has a position as Adjunct Professor in immunology at the University of Turku, Finland.
DelSiTech is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biopharmaceuticals and viral vectors. We focus on parenteral and local administration of drug products.